Welcome to BlogNotions' Life Sciences Blog

The BlogNotions Life Sciences Blog delivers a diverse series of perspectives provided by thought leaders in the life sciences industries. Presented by NetLine, this forum delivers compelling updates on the latest technological advances, discussions of research and findings, best practices for advancing education, implications for the future of various life sciences fields, and much more. Here you can find helpful information, ask questions, and collaborate freely.

Old Drug Boosts Brain’s Memory Centers

 A long-used drug called methylene blue may rev up activity in brain regions involved in short-term memory and attention, a small study suggests.  methylene blue Methylene blue has been used in medicine for more than a century, said Timothy Duong, the senior researcher on the study and a professor at the University of Texas Health […]

Continue Reading

Epclusa Approved for Chronic Hepatitis C

The combination drug Epclusa has been approved by the U.S. Food and Drug Administration to treat the six major strains of chronic hepatitis C virus (HCV). Epclusa combines sofosbuvir, FDA-approved in 2013, and the new drug velpatasvir. For people with moderate-to-severe cirrhosis (chronic liver disease), Epclusa is approved to be used in combination with the […]

Continue Reading

Drug Patent Expirations for Mar 9, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. EVISTA (raloxifene hydrochloride) Lilly Patent number: 6,458,811 Expiration Date: Mar 10, 2017 EVISTA (raloxifene hydrochloride) Lilly Patent number: 6,894,064 Expiration Date: Mar 10, 2017 EVISTA (raloxifene […]

Continue Reading

3 Tips for Finding the Right Talent for Your Biotech Startup

This is a guest post from Steve Kirsh. Steve is Founder + Managing Partner of Khameleon Group. When was the last time you used a matchmaking service? Chances are it was today. Platforms like Amazon, Airbnb, eBay and Uber (as well as the proverbial dating sites) have transformed matchmaking into an everyday adventure in which […]

Continue Reading

Drug Patent Expirations for Feb 23, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. TAMIFLU (oseltamivir phosphate) Roche Patent number: 5,763,483 Expiration Date: Feb 23, 2017 DrugPatentWatch provides instant access to actionable insights on pharmaceutical drugs. For more information try […]

Continue Reading

Drug Patent Expirations for Feb 9, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. AZILECT (rasagiline mesylate) Teva Patent number: 5,453,446 Expiration Date: Feb 7, 2017 ELOXATIN (oxaliplatin) Sanofi Aventis Us Patent number: 5,420,319 Expiration Date: Feb 9, 2017 KYNAMRO […]

Continue Reading

Patent misuse in the Pharmaceutical sector

This is a guest post from Avneet Heer, a student in the MS Biotechnology BioBusiness Track at Georgetown University. Do you have a response to Avneet’s post? Respond in the comments section below. Politics, lobbying and monetary incentives have an increasing influence upon patent policy, especially drug patent policy. This has led to concerns over […]

Continue Reading

Biotech venture capital investments in public equities and performance

How do biotech venture investments in public equities (known as VIPEs) perform? Do they outperform mutual funds and hedge funds? While anecdotal evidence points to some really successful investments (e.g. Abingworth’s investment in Algeta in February 2009 (24x deal return)), this analysis of a large sample of VIPEs  in the biotechnology and pharmaceutical industry over […]

Continue Reading

Leaving money on the table in venture-backed biotechnology IPOs

How do biotech stocks behave during the first day of trading? How do they perform in the long-run period? What is the link between first-day return and aftermarket performance? This study examines these questions using a large sample of U.S. venture-backed biotechnology IPOs during 1980 through 2015. The analysis of first-day returns (underpricing) of venture-backed […]

Continue Reading